Inotek Pharmaceuticals announced positive results for INO-8875 from a Phase I/II trial for patients with glaucoma.  The randomized, double-blind, placebo-controlled clinical trial showed that INO-8875 significantly lowered IOP and was well tolerated.

INO-8875 represents a new approach to treating glaucoma by increasing the outflow of ocular fluid through the trabecular meshwork.

Eighty-four patients participated in the phase I/II study which was designed to evaluate the efficacy, safety and tolerability of topically administered INO-8875. The IOP was measured at multiple time points throughout the study and dose-dependent reductions in IOP were observed. Significant reductions in IOP were found at the two highest doses of INO-8875 tested compared to placebo.

Full results will be presented at a future medical meeting.

Read ^[1] the release.